Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-Adhoc: Aladdin Healthcare Technologies sets up Joint Venture with Chinese partner network and wins new customer - first sales revenues of EUR 120,000

eqs_en 
0 0 29.04.20
DGAP-Adhoc: Aladdin Healthcare Technologies sets up Joint Venture with Chinese partner network and wins new customer - first sales revenues of EUR 120,000
 

DGAP-Ad-hoc: Aladdin Healthcare Technologies SE / Key word(s): Joint Venture
Aladdin Healthcare Technologies sets up Joint Venture with Chinese partner network and wins new customer - first sales revenues of EUR 120,000

29-Apr-2020 / 12:45 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies sets up Joint Venture with Chinese partner network and wins new customer - first sales revenues of EUR 120,000


BERLIN/LONDON, April 29, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of AI healthcare diagnostics and drug discovery applications, has just founded Aladdin Healthcare Technologies China Ltd. together with an extensive network of scientists, pharmacologists and healthcare practitioners including IIAT.

The goal of the joint venture (JV), in which Aladdin Healthcare holds a 51% stake, is the further global development and marketing of an AI-based drug discovery tool. The tool supports basic clinical research for the development of new drugs for age-related diseases such as Alzheimer's, cardiovascular diseases, pulmonary diseases, diabetes and osteoporosis.

At the same time, Aladdin has gained a new customer. The order volume for the use of the AI platform and for consultancy services is EUR 120,000.


For further information

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: [email protected]
Website Link: www.aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone +49 89 1250 90330
Email: [email protected]
www.crossalliance.de

29-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Aladdin Healthcare Technologies SE
Unter den Linden 10
10117 Berlin
Germany
Phone: 030 700140449
E-mail: [email protected]
Internet: www.aladdinid.com
ISIN: DE000A12ULL2
WKN: A12ULL
Listed: Regulated Market in Dusseldorf
EQS News ID: 1032909

 
End of Announcement DGAP News Service

1032909  29-Apr-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1032909&application_name=news&site_id=sharewise

Aladdin Healthcare Technologies SE Stock

€0.014
-37.250%
Aladdin Healthcare Technologies SE took a tumble today and lost €0.000 (-37.250%).

Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!